{"id":2085,"date":"2026-06-21T08:23:40","date_gmt":"2026-06-21T08:23:40","guid":{"rendered":"https:\/\/one-peptides.com\/?p=2085"},"modified":"2026-10-03T14:56:45","modified_gmt":"2026-10-03T14:56:45","slug":"peg-mgf-pegylated-mechano-growth-factor-what-the-research-says-about-muscle-regeneration","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/de\/peg-mgf-pegylated-mechano-growth-factor-what-the-research-says-about-muscle-regeneration\/","title":{"rendered":"PEG-MGF \u2014 pegylated Mechano Growth Factor. What the research says about muscle regeneration"},"content":{"rendered":"
\n\tHome<\/a>\n<\/span>\u00bb<\/span>\n\tRegeneration & research peptides<\/a>\n<\/span>\u00bb<\/span>\n\tPEG-MGF \u2014 pegylated Mechano Growth Factor. What the research says about muscle regeneration\n<\/span><\/div><\/div>\n

Most peptides in the GH\u2013IGF1 axis cluster act indirectly \u2014 secretagogues such as CJC-1295 or Ipamorelin stimulate the pituitary to release growth hormone, which only then triggers hepatic production of IGF-1. PEG-MGF<\/strong> escapes this scheme. Mechano Growth Factor is itself a splice variant of the IGF1 gene \u2014 an isoform that arises locally in skeletal muscle, in direct response to mechanical loading and microdamage to the fibres. There is no pituitary stimulation here \u2014 the action plays out a level lower, at the muscle tissue itself. Hence the name: mechano<\/em> growth factor, a growth factor that responds to mechanics.<\/p>\n

For a researcher working on the GHS cluster, this means a distinct axis of action. Where secretagogues modulate a systemic signal, MGF interests scientists as a factor of the early phase of muscle tissue repair \u2014 through the activation of satellite cells, the myogenic stem cells that lie dormant beside the fibre. The PEG<\/strong> prefix refers to pegylation: the attachment of a polyethylene glycol chain, which extends the exceptionally short half-life of native MGF. This article brings together what the published literature \u2014 overwhelmingly preclinical \u2014 says about the mechanism of MGF, its relationship with classical IGF-1, and the regulatory status of this class of compounds.<\/p>\n

PEG-MGF<\/strong> is the pegylated form of Mechano Growth Factor (MGF) \u2014 a splice variant of insulin-like growth factor IGF-1 (the IGF-1Ec isoform), which arises in muscle in response to mechanical loading. Pegylation extends the half-life of the highly unstable native peptide. Studied in preclinical models of muscle regeneration. A chemical reagent for laboratory research use only (Research Use Only).<\/em><\/p>\n

The article below is educational in nature and constitutes a review of the published scientific literature. The vast majority of the data cited comes from animal models and in vitro studies \u2014 human data are scarce. The text does not constitute medical, pharmaceutical or training advice. PEG-MGF in the One Peptides catalogue is a chemical reagent for laboratory research use only (Research Use Only) and is not intended for administration to humans or animals.<\/em><\/p>\n

What PEG-MGF is<\/h2>\n

MGF, or Mechano Growth Factor, is one of the isoforms arising from the IGF1 gene through alternative splicing of mRNA. The same gene that encodes classical, circulating IGF-1 can \u2014 depending on the tissue and the stimulus \u2014 be “read” differently, yielding a transcript with a distinct terminal fragment. The isoform relevant to muscle carries the designation IGF-1Ec<\/strong> in human nomenclature, with IGF-1Eb as its counterpart in rodents. Its distinguishing feature is a unique C-terminal peptide<\/strong> \u2014 a short stretch of amino acids that is absent from the mature form of systemic IGF-1. It is precisely this C-terminal fragment that is credited with the distinct, early function of MGF in regeneration.<\/p>\n

The problem with native MGF lies in its instability. In the circulation the peptide undergoes rapid degradation \u2014 its estimated half-life is measured in minutes. For a researcher seeking to maintain a stable reagent concentration in an experimental system, this is a serious limitation. Hence the modification: pegylation<\/strong>, the covalent attachment of a polyethylene glycol (PEG) chain to the peptide molecule. Pegylation increases the molecule’s hydrodynamic radius, slows its renal filtration and shields the peptide from proteases, which together substantially extend the time the compound remains present in solution and in the model system (Roberts et al. 2012, general principles of peptide pegylation). The result is PEG-MGF<\/strong> \u2014 a pegylated derivative that retains the C-terminal motif of MGF but has a far more favourable stability profile than the native form.<\/p>\n

Class: regenerative peptide \/ IGF-1 splice variant. In reagent catalogues PEG-MGF is sometimes grouped together with secretagogues of the GH\u2013IGF1 axis for commercial reasons; mechanistically, however, it should be treated as a separate case.<\/p>\n

Mechanism \u2014 satellite cell activation<\/h2>\n

The physiological context of MGF is fairly specific. When a muscle fibre experiences mechanical loading or microdamage \u2014 in models this has been studied following overload, stretch and experimental injury \u2014 expression of the MGF isoform rises sharply in the tissue. The peptide acts locally, at the site of damage, rather than as a systemic signal. Its presumed role is the activation of satellite cells<\/strong> (Hill and Goldspink 2003).<\/p>\n

Satellite cells are myogenic stem cells that lie dormant beneath the basal lamina of the muscle fibre. In healthy, unloaded muscle they remain quiescent. A stimulus in the form of damage triggers their activation: the cells exit the resting state, enter a cycle of divisions (proliferation), and some of them differentiate and fuse with existing fibres or form new ones, participating in tissue repair. In research models MGF is associated precisely with the early stage of this cascade<\/strong> \u2014 the phase in which the pool of satellite cells expands, before differentiation occurs.<\/p>\n

Here lies the essence of the mechanism’s distinctiveness. In the proposed model (Yang and Goldspink 2002) MGF acts within an early window of regeneration \u2014 it stimulates proliferation and expands the pool of satellite cells \u2014 and only later does classical, systemic IGF-1 take over the phase of differentiation and maturation of new fibres. This temporal separation of two isoforms of the same gene is a central element of the hypothesis put forward by Goldspink and his collaborators. Growth hormone secretagogues act in an entirely different way: they modulate the GH\u2013IGF1 axis systemically<\/strong>, raising overall levels of growth hormone and hepatic IGF-1, without this local, mechanically dependent specificity.<\/p>\n

It should be emphasised that the receptor-level details of how the C-terminal peptide of MGF acts remain the subject of research and debate. Some studies suggest that the unique C-terminal fragment may act independently of the main IGF-1 receptor (IGF-1R), although this is not a settled question in the literature.<\/p>\n

MGF versus IGF-1 \u2014 what the difference is<\/h2>\n

The crux of the matter can be put in a single sentence: MGF and IGF-1 are two products of the same gene<\/strong>, differing in their C-terminal fragment, their site of origin and their function over the course of regeneration.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nIGF-1 (systemic)<\/th>\nMGF (Mechano Growth Factor)<\/th>\n<\/tr>\n<\/thead>\n
Origin<\/td>\nSplice variant of the IGF1 gene<\/td>\nSplice variant of the IGF1 gene (IGF-1Ec \/ IGF-1Eb isoform)<\/td>\n<\/tr>\n
Main site of production<\/td>\nLiver (systemic signal)<\/td>\nSkeletal muscle (locally, at the site of loading)<\/td>\n<\/tr>\n
Stimulus<\/td>\nGH axis \u2014 growth hormone from the pituitary<\/td>\nMechanical loading, microdamage to the fibre<\/td>\n<\/tr>\n
C-terminus of the peptide<\/td>\nStandard<\/td>\nUnique, distinct C-terminal stretch<\/td>\n<\/tr>\n
Presumed phase of regeneration<\/td>\nDifferentiation and maturation of fibres (later)<\/td>\nActivation and proliferation of satellite cells (early)<\/td>\n<\/tr>\n
Range of action<\/td>\nSystemic, endocrine<\/td>\nLocal, auto-\/paracrine<\/td>\n<\/tr>\n
Half-life of the native form<\/td>\nExtended by binding proteins (IGFBP)<\/td>\nVery short (minutes) \u2014 hence the pegylation modification<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

In short: IGF-1 is the systemic, hepatic arm responsible for the differentiation phase. MGF is the local, muscular arm linked to the satellite cell activation phase. Both arise from the same gene, but alternative splicing gives them a different C-terminus and \u2014 in the proposed model \u2014 a different temporal role in tissue repair. PEG-MGF is the pegylated, more stable derivative of the latter, muscular isoform.<\/p>\n

What the research says<\/h2>\n

The foundation of knowledge about MGF was built by the team of Geoffrey Goldspink<\/strong> \u2014 it was his work that first described the mechanically dependent splice isoform of IGF-1 and linked it to the muscle’s response to loading. The summary below outlines the nature of the available literature. It must be read with one caveat: almost the entire evidence base comes from animal models (chiefly rodents) and in vitro cell cultures.<\/p>\n

Data concerning MGF and PEG-MGF come for the most part from animal models and in vitro studies<\/strong> (myoblast cultures, models of muscle injury and overload in rodents). Studies in humans concerning externally administered MGF\/PEG-MGF are very few<\/strong>, and the available mechanistic data in humans relate mainly to endogenous expression of the isoform after exercise, rather than to administration of the peptide. Any extrapolation of these observations to humans remains speculative.<\/em><\/p>\n\n\n\n\n\n\n\n\n
Study \/ authors<\/th>\nModel<\/th>\nObservation<\/th>\nYear<\/th>\n<\/tr>\n<\/thead>\n
Yang & Goldspink<\/td>\nMyoblast culture (in vitro)<\/td>\nC-terminal peptide of MGF linked to proliferation and delayed differentiation of myoblasts \u2014 suggesting a distinct, early function<\/td>\n2002<\/td>\n<\/tr>\n
Hill & Goldspink<\/td>\nRat muscle, injury\/overload model<\/td>\nIncreased MGF expression following injury, linked to satellite cell activation<\/td>\n2003<\/td>\n<\/tr>\n
Goldspink (review)<\/td>\nReview \/ synthesis<\/td>\nConcept of mechanically dependent IGF-1 splicing and the separation of function between MGF and systemic IGF-1<\/td>\n2005<\/td>\n<\/tr>\n
Review of IGF-1 isoforms<\/td>\nLiterature review<\/td>\nCharacterisation of the IGF-1Ec\/IGF-1Eb isoforms and their role in muscle<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The conclusion drawn from the literature as a whole is cautious. Goldspink’s hypothesis \u2014 that MGF constitutes an early, local signal activating satellite cells, temporally distinct from systemic IGF-1 \u2014 is mechanistically coherent and supported by preclinical data. It is not, however, equivalent to a demonstration that externally administered<\/strong> PEG-MGF produces a meaningful, reproducible repair effect in humans. The published literature does not fill that gap.<\/p>\n

Safety and WADA status<\/h2>\n

Growth factors \u2014 including IGF-1 and its variants and derivatives \u2014 belong to a class of compounds banned in sport. The World Anti-Doping Agency (WADA) places peptide growth factors and factors modulating the GH\/IGF-1 axis in category S2<\/strong> (peptide hormones, growth factors, related substances and mimetics). MGF, as a splice variant of IGF-1, falls within this class. Athletes subject to anti-doping testing should treat PEG-MGF as a prohibited substance and verify the current wording of the WADA list, which is updated annually.<\/p>\n

From the perspective of the safety profile, a conditional caveat applies that follows directly from the state of the research. The data come from preclinical models; there are no long-term, controlled studies in humans<\/strong> concerning the administration of PEG-MGF. Any discussion of risk is therefore theoretical in nature and rests on general knowledge of the growth factor class \u2014 compounds that signal cellular proliferation are the subject of research caution, and their full profile in the context of external administration in humans has not been characterised. This is a further reason why the RUO status of this reagent is unambiguous.<\/p>\n

PEG-MGF as a research reagent<\/h2>\n

In the One Peptides catalogue PEG-MGF is available as a lyophilisate in the PEG-MGF 5 mg<\/a><\/strong> variant, classified as a chemical reagent for laboratory research use only (Research Use Only). For a researcher assessing a reagent’s suitability for an experiment, the decisive factors are the quality parameters, not the trade name. Each batch undergoes purity analysis by high-performance liquid chromatography with a threshold of HPLC \u226598%<\/strong>, and the identity of the peptide is confirmed by mass spectrometry (MS). The binding document remains the certificate of analysis (COA)<\/a><\/strong> issued for the given batch \u2014 it states the declared purity, the measured mass and the batch number that allows the origin to be traced.<\/p>\n

With pegylated reagents it is worth noting that the mass measured by MS will be higher than the mass of the peptide core alone by the mass of the attached PEG chain \u2014 this is an expected feature, not an anomaly, and the COA should describe the pegylated form unambiguously. The lyophilisate requires storage in a cold chain at 2\u20138\u00b0C and protection from light; to prepare the working solution, reconstitution in a suitable solvent is used, in accordance with the internal laboratory protocol and observing the sterility rules in force in the given laboratory.<\/p>\n

Frequently asked questions<\/h2>\n

What is PEG-MGF?<\/strong><\/p>\n

PEG-MGF is the pegylated form of Mechano Growth Factor (MGF) \u2014 a splice isoform of the IGF1 gene (IGF-1Ec) which arises locally in skeletal muscle in response to mechanical loading. The PEG prefix denotes the attachment of a polyethylene glycol chain, which extends the very short half-life of the native peptide. In the catalogue it is available as a reagent for laboratory research (RUO).<\/p>\n

PEG-MGF versus IGF-1 \u2014 what is the difference?<\/strong><\/p>\n

Both compounds are splice variants of the same IGF1 gene, but they differ in their C-terminal fragment, their site of origin and their role over time. Systemic IGF-1 is produced mainly in the liver under the influence of growth hormone and is linked to the fibre differentiation phase. MGF arises locally in muscle after loading and \u2014 in the proposed model \u2014 acts earlier, at the stage of activation and proliferation of satellite cells.<\/p>\n

MGF and muscle regeneration \u2014 what does the research say?<\/strong><\/p>\n

Animal models and in vitro cell cultures link MGF to the early phase of muscle tissue repair \u2014 to the activation of satellite cells after damage to the fibre (work by Goldspink’s team). It must be noted, however, that data concerning externally administered<\/strong> MGF\/PEG-MGF in humans are very sparse, and most of the observations come from outside human clinical studies. The mechanistic hypothesis is coherent, but it does not amount to proof of efficacy in humans.<\/p>\n

Why is pegylation (PEG) used?<\/strong><\/p>\n

Native MGF is exceptionally unstable \u2014 in the circulation it degrades within minutes. Pegylation, the covalent attachment of a polyethylene glycol chain, increases the size of the molecule, slows its elimination and shields the peptide from proteases. The result is a longer time during which the compound is present in solution and in the model system, which makes it a more practical research reagent than the native form.<\/p>\n

Is PEG-MGF on the WADA list?<\/strong><\/p>\n

Yes. Peptide growth factors and substances modulating the GH\/IGF-1 axis are in category S2<\/strong> of the WADA list of prohibited substances, and MGF as a variant of IGF-1 falls within this class. Athletes subject to anti-doping testing should treat PEG-MGF as a prohibited substance and check the current wording of the list, which is updated annually.<\/p>\n

Related content in the knowledge base<\/h2>\n